Maximus, Inc. (MMS) Stock Rating Lowered by Zacks Investment Research

Maximus, Inc. (NYSE:MMS) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Tuesday.

According to Zacks, “MAXIMUS, Inc. is an extremely dynamic and complex organization that offers government and industry a range of unique services, products, and solutions. The diverse services and products that MAXIMUS offers may be categorized into three groups: Government Program Management and Operations, Consulting, and Systems. Government Program Management and Operations focuses on having a measurable impact on the lives of the citizens we help government serve. The insights of MAXIMUS Consulting, and the technological innovations advanced through Systems, help government gain program efficiencies and pursue improvements that in turn benefit citizens. “

MMS has been the subject of a number of other reports. Robert W. Baird initiated coverage on shares of Maximus in a report on Sunday, September 3rd. They set a “neutral” rating for the company. BidaskClub lowered shares of Maximus from a “strong-buy” rating to a “buy” rating in a report on Thursday, July 6th. Maxim Group set a $66.00 price target on shares of Maximus and gave the company a “hold” rating in a report on Thursday, August 3rd. Finally, Canaccord Genuity lowered shares of Maximus from a “buy” rating to a “hold” rating and set a $62.00 price target for the company. in a report on Tuesday, July 4th. One research analyst has rated the stock with a sell rating and nine have assigned a hold rating to the stock. Maximus currently has a consensus rating of “Hold” and a consensus target price of $63.14.

Maximus (NYSE MMS) traded up 0.24% during trading on Tuesday, hitting $65.53. 10,111 shares of the company’s stock traded hands. Maximus has a 12-month low of $43.69 and a 12-month high of $66.38. The firm’s 50-day moving average price is $62.92 and its 200 day moving average price is $61.92. The stock has a market cap of $4.25 billion, a P/E ratio of 21.00 and a beta of 1.36.

Maximus (NYSE:MMS) last released its quarterly earnings data on Thursday, August 3rd. The health services provider reported $0.79 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.76 by $0.03. Maximus had a net margin of 8.43% and a return on equity of 25.08%. The company had revenue of $600.40 million during the quarter, compared to analyst estimates of $614.12 million. During the same quarter in the prior year, the business earned $0.79 earnings per share. The business’s quarterly revenue was down 2.7% compared to the same quarter last year. Analysts anticipate that Maximus will post $3.13 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece was published by Markets Daily and is the property of of Markets Daily. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.themarketsdaily.com/2017/10/12/maximus-inc-mms-stock-rating-lowered-by-zacks-investment-research.html.

In other Maximus news, CEO Richard A. Montoni sold 29,203 shares of the stock in a transaction on Thursday, August 17th. The shares were sold at an average price of $60.38, for a total transaction of $1,763,277.14. Following the transaction, the chief executive officer now directly owns 549,215 shares in the company, valued at approximately $33,161,601.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, President Bruce Caswell sold 8,000 shares of the stock in a transaction on Thursday, July 27th. The shares were sold at an average price of $60.97, for a total transaction of $487,760.00. Following the transaction, the president now owns 35,904 shares in the company, valued at $2,189,066.88. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 152,403 shares of company stock valued at $9,414,501. Company insiders own 3.10% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of MMS. BlackRock Inc. boosted its stake in Maximus by 22,491.0% during the 1st quarter. BlackRock Inc. now owns 6,503,511 shares of the health services provider’s stock valued at $404,518,000 after acquiring an additional 6,474,723 shares during the last quarter. Janus Henderson Group PLC boosted its stake in Maximus by 718.8% during the 2nd quarter. Janus Henderson Group PLC now owns 2,211,638 shares of the health services provider’s stock valued at $138,515,000 after acquiring an additional 1,941,521 shares during the last quarter. Clearbridge Investments LLC boosted its stake in Maximus by 49.5% during the 1st quarter. Clearbridge Investments LLC now owns 2,004,270 shares of the health services provider’s stock valued at $124,666,000 after acquiring an additional 663,189 shares during the last quarter. Koch Industries Inc. bought a new position in Maximus during the 2nd quarter valued at $629,000. Finally, FMR LLC boosted its stake in Maximus by 10.4% during the 2nd quarter. FMR LLC now owns 4,658,584 shares of the health services provider’s stock valued at $291,767,000 after acquiring an additional 438,025 shares during the last quarter. Hedge funds and other institutional investors own 97.23% of the company’s stock.

About Maximus

MAXIMUS, Inc provides business process services (BPS) to government health and human services agencies. The Company operates through three segments: U.S. Federal Services, Health Services and Human Services. The U.S. Federal Services segment provides BPS and program management for large government programs, independent health review and appeals services for both the United States Federal Government, and state-based programs and technology solutions for civilian federal programs.

Analyst Recommendations for Maximus (NYSE:MMS)

Receive News & Ratings for Maximus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maximus Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply